Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nat Rev Clin Oncol 2022;19:515–533.

• PubMed
Qiu B, Matthay KK. Advancing therapy for neuroblastoma. Nat Rev Clin Oncol 2022;19:515–533.)| false
• Search Google Scholar
• Export Citation

Neuroblastoma Treatment (PDQ®): Health Professional Version. 2023 Aug 22. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002. 2023. Accessed November 30, 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK65747/

• PubMed
Neuroblastoma Treatment (PDQ®): Health Professional Version. 2023 Aug 22. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002. 2023. Accessed November 30, 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK65747/)| false
• Search Google Scholar
• Export Citation

About Neuroblastoma. Accessed November 30, 2023. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8758.00.pdf

• PubMed
About Neuroblastoma. Accessed November 30, 2023. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8758.00.pdf)| false
• Search Google Scholar
• Export Citation

Siegel DA, King JB, Lupo PJ, et al. Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019. J Natl Cancer Inst 2023;115:1337–1354.

• PubMed
Siegel DA, King JB, Lupo PJ, Counts, incidence rates, and trends of pediatric cancer in the United States, 2003-2019. J Natl Cancer Inst 2023;115:1337–1354.)| false
• Search Google Scholar
• Export Citation

Neuroblastoma. PathologyOutlines.com website. 2023. Accessed April 30, 2024. Available at: https://www.pathologyoutlines.com/topic/adrenalneuroblastoma.html

• PubMed
Neuroblastoma. PathologyOutlines.com website. 2023. Accessed April 30, 2024. Available at: https://www.pathologyoutlines.com/topic/adrenalneuroblastoma.html)| false
• Search Google Scholar
• Export Citation

Bagatell R, DuBois SG, Naranjo A, et al. Children’s Oncology Group’s 2023 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2023;70:e30572.

• PubMed
Bagatell R, DuBois SG, Naranjo A, Children’s Oncology Group’s 2023 blueprint for research: neuroblastoma. Pediatr Blood Cancer 2023;70:e30572.)| false
• Search Google Scholar
• Export Citation

Henderson TO, Bhatia S, Pinto N, et al. Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children’s Oncology Group study. J Clin Oncol 2011;29:76–82.

• PubMed
Henderson TO, Bhatia S, Pinto N, Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children’s Oncology Group study. J Clin Oncol 2011;29:76–82.)| false
• Search Google Scholar
• Export Citation

Bona K, Li Y, Winestone LE, et al. Poverty and targeted immunotherapy: survival in Children’s Oncology Group clinical trials for high-risk neuroblastoma. J Natl Cancer Inst 2021;113:282–291.

• PubMed
Bona K, Li Y, Winestone LE, Poverty and targeted immunotherapy: survival in Children’s Oncology Group clinical trials for high-risk neuroblastoma. J Natl Cancer Inst 2021;113:282–291.)| false
• Search Google Scholar
• Export Citation

Campbell K, Siegel DA, Umaretiya PJ, et al. A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019. Pediatr Blood Cancer 2024;71:e30732

• PubMed
Campbell K, Siegel DA, Umaretiya PJ, A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019. Pediatr Blood Cancer 2024;71:e30732)| false
• Search Google Scholar
• Export Citation

National Institutes of Health. PubMed Overview. Available at: https://pubmed.ncbi.nlm.nih.gov/about/

• PubMed
National Institutes of Health. PubMed Overview. Available at: https://pubmed.ncbi.nlm.nih.gov/about/)| false
• Search Google Scholar
• Export Citation

Freedman-Cass DA, Fischer T, Alpert AB, et al. The value and process of inclusion: using sensitive, respectful, and inclusive language and images in NCCN content. J Natl Compr Canc Netw 2023;21:434–441.

• PubMed
Freedman-Cass DA, Fischer T, Alpert AB, The value and process of inclusion: using sensitive, respectful, and inclusive language and images in NCCN content. J Natl Compr Canc Netw 2023;21:434–441.)| false
• Search Google Scholar
• Export Citation

Matthay KK, Maris JM, Schleiermacher G, et al. Neuroblastoma. Nat Rev Dis Primers 2016;2:16078

• PubMed
Matthay KK, Maris JM, Schleiermacher G, Neuroblastoma. Nat Rev Dis Primers 2016;2:16078)| false
• Search Google Scholar
• Export Citation

Kamihara J, Bourdeaut F, Foulkes WD, et al. Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res 2017;23:e98–106.

• PubMed
Kamihara J, Bourdeaut F, Foulkes WD, Retinoblastoma and neuroblastoma predisposition and surveillance. Clin Cancer Res 2017;23:e98–106.)| false
• Search Google Scholar
• Export Citation

Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930–935.

• PubMed
Mosse YP, Laudenslager M, Longo L, Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008;455:930–935.)| false
• Search Google Scholar
• Export Citation

Janoueix-Lerosey I, Lequin D, Brugieres L, et al. Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967–970.

• PubMed
Janoueix-Lerosey I, Lequin D, Brugieres L, Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 2008;455:967–970.)| false
• Search Google Scholar
• Export Citation

Trochet D, Bourdeaut F, Janoueix-Lerosey I, et al. Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 2004;74:761–764.

• PubMed
Trochet D, Bourdeaut F, Janoueix-Lerosey I, Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am J Hum Genet 2004;74:761–764.)| false
• Search Google Scholar
• Export Citation

Witkowski L, Nichols KE, Jongmans M, et al. Germline pathogenic SMARCA4 variants in neuroblastoma. J Med Genet 2023;60:987–992.

• PubMed
Witkowski L, Nichols KE, Jongmans M, Germline pathogenic SMARCA4 variants in neuroblastoma. J Med Genet 2023;60:987–992.)| false
• Search Google Scholar
• Export Citation

Kim J, Vaksman Z, Egolf LE, et al. Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival. J Natl Cancer Inst 2024;116:149–159.

• PubMed
Kim J, Vaksman Z, Egolf LE, Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival. J Natl Cancer Inst 2024;116:149–159.)| false
• Search Google Scholar
• Export Citation

Newly diagnosed with neuroblastoma. 2011. Accessed April 30, 2024. Available at: https://www.childrensoncologygroup.org/newly-diagnosed-with-neuroblastoma

• PubMed
Newly diagnosed with neuroblastoma. 2011. Accessed April 30, 2024. Available at: https://www.childrensoncologygroup.org/newly-diagnosed-with-neuroblastoma)| false
• Search Google Scholar
• Export Citation

Neuroblastoma Early Detection, Diagnosis, and Staging. 2021. Accessed November 30, 2023. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8760.00.pdf

• PubMed
Neuroblastoma Early Detection, Diagnosis, and Staging. 2021. Accessed November 30, 2023. Available at: https://www.cancer.org/content/dam/CRC/PDF/Public/8760.00.pdf)| false
• Search Google Scholar
• Export Citation

Pang KK, de Sousa C, Lang B, Pike MG. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol 2010;14:156–161.

• PubMed
Pang KK, de Sousa C, Lang B, Pike MG. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol 2010;14:156–161.)| false
• Search Google Scholar
• Export Citation

Rossor T, Yeh EA, Khakoo Y, et al. Diagnosis and management of opsoclonus-myoclonus-ataxia syndrome in children: an international perspective. Neurol Neuroimmunol Neuroinflamm 2022;9:e1153

• PubMed
Rossor T, Yeh EA, Khakoo Y, Diagnosis and management of opsoclonus-myoclonus-ataxia syndrome in children: an international perspective. Neurol Neuroimmunol Neuroinflamm 2022;9:e1153)| false
• Search Google Scholar
• Export Citation

Hasegawa S, Matsushige T, Kajimoto M, et al. A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children. Brain Dev 2015;37:656–660.

• PubMed
Hasegawa S, Matsushige T, Kajimoto M, A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children. Brain Dev 2015;37:656–660.)| false
• Search Google Scholar
• Export Citation

Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs 2005;22:8–19.

• PubMed
Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs 2005;22:8–19.)| false
• Search Google Scholar
• Export Citation

Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349–363.

• PubMed
Shimada H, Ambros IM, Dehner LP, Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349–363.)| false
• Search Google Scholar
• Export Citation

Shimada H, Ambros IM, Dehner LP, et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364–372.

• PubMed
Shimada H, Ambros IM, Dehner LP, The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364–372.)| false
• Search Google Scholar
• Export Citation

Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466–1477.

• PubMed
Brodeur GM, Pritchard J, Berthold F, Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993;11:1466–1477.)| false
• Search Google Scholar
• Export Citation

Twist CJ, Schmidt ML, Naranjo A, et al. Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: a report from the Children’s Oncology Group study ANBL0531. J Clin Oncol 2019;37:3243–3255.

• PubMed
Twist CJ, Schmidt ML, Naranjo A, Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: a report from the Children’s Oncology Group study ANBL0531. J Clin Oncol 2019;37:3243–3255.)| false
• Search Google Scholar
• Export Citation

Nuchtern JG, London WB, Barnewolt CE, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surg 2012;256:573–580.

• PubMed
Nuchtern JG, London WB, Barnewolt CE, A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surg 2012;256:573–580.)| false
• Search Google Scholar
• Export Citation

Williams CM, Greer M. Homovanillic acid and vanilmandelic acid in diagnosis of neuroblastoma. JAMA 1963;183:836–840.

• PubMed
Williams CM, Greer M. Homovanillic acid and vanilmandelic acid in diagnosis of neuroblastoma. JAMA 1963;183:836–840.)| false
• Search Google Scholar
• Export Citation

Moroz V, Machin D, Hero B, et al. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer 2020;67:e28359.

• PubMed
Moroz V, Machin D, Hero B, The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: a report from the International Neuroblastoma Risk Group (INRG) project. Pediatr Blood Cancer 2020;67:e28359.)| false
• Search Google Scholar
• Export Citation

Irwin MS, Naranjo A, Zhang FF, et al. Revised Neuroblastoma Risk Classification System: a report from the Children’s Oncology Group. J Clin Oncol 2021;39:3229–3241.

• PubMed
Irwin MS, Naranjo A, Zhang FF, Revised Neuroblastoma Risk Classification System: a report from the Children’s Oncology Group. J Clin Oncol 2021;39:3229–3241.)| false
• Search Google Scholar
• Export Citation

Pinches RS, Clinton CM, Ward A, et al. Making the most of small samples: optimization of tissue allocation of pediatric solid tumors for clinical and research use. Pediatr Blood Cancer 2020;67:e28326.

• PubMed
Pinches RS, Clinton CM, Ward A, Making the most of small samples: optimization of tissue allocation of pediatric solid tumors for clinical and research use. Pediatr Blood Cancer 2020;67:e28326.)| false
• Search Google Scholar
• Export Citation

Fisch AS, Church AJ. Special considerations in the molecular diagnostics of pediatric neoplasms. Clin Lab Med 2022;42:349–365.

• PubMed
Fisch AS, Church AJ. Special considerations in the molecular diagnostics of pediatric neoplasms. Clin Lab Med 2022;42:349–365.)| false
• Search Google Scholar
• Export Citation

Burchill SA, Beiske K, Shimada H, et al. Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer 2017;123:1095–1105.

• PubMed
Burchill SA, Beiske K, Shimada H, Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group. Cancer 2017;123:1095–1105.)| false
• Search Google Scholar
• Export Citation

Oh C, Youn JK, Han JW, et al. Abdominal tumors in children: comparison between minimally invasive surgery and traditional open surgery. Medicine (Baltimore) 2016;95:e5181.

• PubMed
Oh C, Youn JK, Han JW, Abdominal tumors in children: comparison between minimally invasive surgery and traditional open surgery. Medicine (Baltimore) 2016;95:e5181.)| false
• Search Google Scholar
• Export Citation

Franquemont DW, Mills SE, Lack EE. Immunohistochemical detection of neuroblastomatous foci in composite adrenal pheochromocytoma-neuroblastoma. Am J Clin Pathol 1994;102:163–170.

• PubMed
Franquemont DW, Mills SE, Lack EE. Immunohistochemical detection of neuroblastomatous foci in composite adrenal pheochromocytoma-neuroblastoma. Am J Clin Pathol 1994;102:163–170.)| false
• Search Google Scholar
• Export Citation

Warren M, Matsuno R, Tran H, Shimada H. Utility of Phox2b immunohistochemical stain in neural crest tumours and non-neural crest tumours in paediatric patients. Histopathology 2018;72:685–696.

• PubMed
Warren M, Matsuno R, Tran H, Shimada H. Utility of Phox2b immunohistochemical stain in neural crest tumours and non-neural crest tumours in paediatric patients. Histopathology 2018;72:685–696.)| false
• Search Google Scholar
• Export Citation

Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics 2002;22:911–934.

• PubMed
Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologic correlation. Radiographics 2002;22:911–934.)| false
• Search Google Scholar
• Export Citation

Brisse HJ, McCarville MB, Granata C, et al. International Neuroblastoma Risk Group Project Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011;261:243–257.

• PubMed
Brisse HJ, McCarville MB, Granata C, International Neuroblastoma Risk Group Project Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 2011;261:243–257.)| false
• Search Google Scholar
• Export Citation

Peuchmaur M, d'Amore ES, Joshi VV, et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003;98:2274–2281.

• PubMed
Peuchmaur M, d'Amore ES, Joshi VV, Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003;98:2274–2281.)| false
• Search Google Scholar
• Export Citation

Brodeur GM, Seeger RC, Schwab M, et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121–1124.

• PubMed
Brodeur GM, Seeger RC, Schwab M, Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121–1124.)| false
• Search Google Scholar
• Export Citation

Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111–1116.

• PubMed
Seeger RC, Brodeur GM, Sather H, Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med 1985;313:1111–1116.)| false
• Search Google Scholar
• Export Citation

Ambros IM, Tonini GP, Potschger U, et al. Age dependency of the prognostic impact of tumor genomics in localized resectable MYCN-nonamplified neuroblastomas. Report from the SIOPEN biology group on the LNESG trials and a COG validation group. J Clin Oncol 2020;38:3685–3697.

• PubMed
Ambros IM, Tonini GP, Potschger U, Age dependency of the prognostic impact of tumor genomics in localized resectable MYCN-nonamplified neuroblastomas. Report from the SIOPEN biology group on the LNESG trials and a COG validation group. J Clin Oncol 2020;38:3685–3697.)| false
• Search Google Scholar
• Export Citation

George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005;23:6466–6473.

• PubMed
George RE, London WB, Cohn SL, Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol 2005;23:6466–6473.)| false
• Search Google Scholar
• Export Citation

Zafar A, Wang W, Liu G, et al. Molecular targeting therapies for neuroblastoma: progress and challenges. Med Res Rev 2021;41:961–1021.

• PubMed
Zafar A, Wang W, Liu G, Molecular targeting therapies for neuroblastoma: progress and challenges. Med Res Rev 2021;41:961–1021.)| false
• Search Google Scholar
• Export Citation

Church AJ, Corson LB, Kao PC, et al. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med 2022;28:1581–1589.

• PubMed
Church AJ, Corson LB, Kao PC, Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer. Nat Med 2022;28:1581–1589.)| false
• Search Google Scholar
• Export Citation

Bresler SC, Weiser DA, Huwe PJ, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014;26:682–694.

• PubMed
Bresler SC, Weiser DA, Huwe PJ, ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell 2014;26:682–694.)| false
• Search Google Scholar
• Export Citation

Bellini A, Potschger U, Bernard V, et al. Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). J Clin Oncol 2021;39:3377–3390.

• PubMed
Bellini A, Potschger U, Bernard V, Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). J Clin Oncol 2021;39:3377–3390.)| false
• Search Google Scholar
• Export Citation

Berlak M, Tucker E, Dorel M, et al. Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. Mol Cancer 2022;21:126.

• PubMed
Berlak M, Tucker E, Dorel M, Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells. Mol Cancer 2022;21:126.)| false
• Search Google Scholar
• Export Citation

Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics 2016;36:258–278.

• PubMed
Sharp SE, Trout AT, Weiss BD, Gelfand MJ. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics 2016;36:258–278.)| false
• Search Google Scholar
• Export Citation

Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010;24:65–86.

• PubMed
Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am 2010;24:65–86.)| false
• Search Google Scholar
• Export Citation

Park JR, Bagatell R, Cohn SL, et al. Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2017;35:2580–2587.

• PubMed
Park JR, Bagatell R, Cohn SL, Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2017;35:2580–2587.)| false
• Search Google Scholar
• Export Citation

Bagatell R, McHugh K, Naranjo A, et al. Assessment of primary site response in children with high-risk neuroblastoma: an international multicenter study. J Clin Oncol 2016;34:740–746.

• PubMed
Bagatell R, McHugh K, Naranjo A, Assessment of primary site response in children with high-risk neuroblastoma: an international multicenter study. J Clin Oncol 2016;34:740–746.)| false
• Search Google Scholar
• Export Citation

Papaioannou G, McHugh K. Neuroblastoma in childhood: review and radiological findings. Cancer Imaging 2005;5:116–127.

• PubMed
Papaioannou G, McHugh K. Neuroblastoma in childhood: review and radiological findings. Cancer Imaging 2005;5:116–127.)| false
• Search Google Scholar
• Export Citation

Yanik GA, Parisi MT, Naranjo A, et al. Validation of postinduction Curie scores in high-risk neuroblastoma: a Children’s Oncology Group and SIOPEN Group report on SIOPEN/HR-NBL1. J Nucl Med 2018;59:502–508.

• PubMed
Yanik GA, Parisi MT, Naranjo A, Validation of postinduction Curie scores in high-risk neuroblastoma: a Children’s Oncology Group and SIOPEN Group report on SIOPEN/HR-NBL1. J Nucl Med 2018;59:502–508.)| false
• Search Google Scholar
• Export Citation

Ladenstein R, Lambert B, Potschger U, et al. Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging 2018;45:292–305.

• PubMed
Ladenstein R, Lambert B, Potschger U, Validation of the mIBG skeletal SIOPEN scoring method in two independent high-risk neuroblastoma populations: the SIOPEN/HR-NBL1 and COG-A3973 trials. Eur J Nucl Med Mol Imaging 2018;45:292–305.)| false
• Search Google Scholar
• Export Citation

Lai HA, Sharp SE, Bhatia A, et al. Imaging of pediatric neuroblastoma: a COG Diagnostic Imaging Committee/SPR Oncology Committee white paper. Pediatr Blood Cancer 2023;70 Suppl 4:e29974.

• PubMed
Lai HA, Sharp SE, Bhatia A, Imaging of pediatric neuroblastoma: a COG Diagnostic Imaging Committee/SPR Oncology Committee white paper. Pediatr Blood Cancer 2023;70 Suppl 4:e29974.)| false
• Search Google Scholar
• Export Citation

Sokol E, Desai AV, Applebaum MA, et al. Age, diagnostic category, tumor grade, and mitosis-karyorrhexis index are independently prognostic in neuroblastoma: an INRG project. J Clin Oncol 2020;38:1906–1918.

• PubMed
Sokol E, Desai AV, Applebaum MA, Age, diagnostic category, tumor grade, and mitosis-karyorrhexis index are independently prognostic in neuroblastoma: an INRG project. J Clin Oncol 2020;38:1906–1918.)| false
• Search Google Scholar
• Export Citation

Janoueix-Lerosey I, Schleiermacher G, Michels E, et al. Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026–1033.

• PubMed
Janoueix-Lerosey I, Schleiermacher G, Michels E, Overall genomic pattern is a predictor of outcome in neuroblastoma. J Clin Oncol 2009;27:1026–1033.)| false
• Search Google Scholar
• Export Citation

Schleiermacher G, Mosseri V, London WB, et al. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer 2012;107:1418–1422.

• PubMed
Schleiermacher G, Mosseri V, London WB, Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Br J Cancer 2012;107:1418–1422.)| false
• Search Google Scholar
• Export Citation

Hsu LL, Evans AE, D’Angio GJ. Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate. Med Pediatr Oncol 1996;27:521–528.

• PubMed
Hsu LL, Evans AE, D’Angio GJ. Hepatomegaly in neuroblastoma stage 4s: criteria for treatment of the vulnerable neonate. Med Pediatr Oncol 1996;27:521–528.)| false
• Search Google Scholar
• Export Citation

Cohn SL, Pearson AD, London WB, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289–297.

• PubMed
Cohn SL, Pearson AD, London WB, The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol 2009;27:289–297.)| false
• Search Google Scholar
• Export Citation

Meany HJ, London WB, Ambros PF, et al. Significance of clinical and biologic features in stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer 2014;61:1932–1939.

• PubMed
Meany HJ, London WB, Ambros PF, Significance of clinical and biologic features in stage 3 neuroblastoma: a report from the International Neuroblastoma Risk Group project. Pediatr Blood Cancer 2014;61:1932–1939.)| false
• Search Google Scholar
• Export Citation

Meany HJ. Non-high-risk neuroblastoma: classification and achievements in therapy. Children (Basel) 2019;6.

• PubMed
Meany HJ. Non-high-risk neuroblastoma: classification and achievements in therapy. Children (Basel) 2019;6.)| false
• Search Google Scholar
• Export Citation

DuBois SG, Macy ME, Henderson TO. High-risk and relapsed neuroblastoma: toward more cures and better outcomes. Am Soc Clin Oncol Educ Book 2022;42:1–13.

• PubMed
DuBois SG, Macy ME, Henderson TO. High-risk and relapsed neuroblastoma: toward more cures and better outcomes. Am Soc Clin Oncol Educ Book 2022;42:1–13.)| false
• Search Google Scholar
• Export Citation

Baker DL, Schmidt ML, Cohn SL, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010;363:1313–1323.

• PubMed
Baker DL, Schmidt ML, Cohn SL, Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. N Engl J Med 2010;363:1313–1323.)| false
• Search Google Scholar
• Export Citation

Strother DR, London WB, Schmidt ML, et al. Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children’s Oncology Group study P9641. J Clin Oncol 2012;30:1842–1848.

• PubMed
Strother DR, London WB, Schmidt ML, Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children’s Oncology Group study P9641. J Clin Oncol 2012;30:1842–1848.)| false
• Search Google Scholar
• Export Citation

Kohler JA, Rubie H, Castel V, et al. Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study. Eur J Cancer 2013;49:3671–3679.

• PubMed
Kohler JA, Rubie H, Castel V, Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: results of the SIOPEN study. Eur J Cancer 2013;49:3671–3679.)| false
• Search Google Scholar
• Export Citation

Kushner BH, Kramer K, LaQuaglia MP, et al. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 2004;22:4888–4892.

• PubMed
Kushner BH, Kramer K, LaQuaglia MP, Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol 2004;22:4888–4892.)| false
• Search Google Scholar
• Export Citation

Pinto N, Naranjo A, Hibbitts E, et al. Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children’s Oncology Group (COG). Eur J Cancer 2019;112:66–79.

• PubMed
Pinto N, Naranjo A, Hibbitts E, Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children’s Oncology Group (COG). Eur J Cancer 2019;112:66–79.)| false
• Search Google Scholar
• Export Citation

Park JR, Scott JR, Stewart CF, et al. Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group study. J Clin Oncol 2011;29:4351–4357.

• PubMed
Park JR, Scott JR, Stewart CF, Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group study. J Clin Oncol 2011;29:4351–4357.)| false
• Search Google Scholar
• Export Citation

Park JR, Kreissman SG, London WB, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA 2019;322:746–755.

• PubMed
Park JR, Kreissman SG, London WB, Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA 2019;322:746–755.)| false
• Search Google Scholar
• Export Citation

Granger MM, Naranjo A, Bagatell R, et al. Myeloablative busulfan/melphalan consolidation following induction chemotherapy for patients with newly diagnosed high-risk neuroblastoma: Children’s Oncology Group trial ANBL12P1. Transplant Cell Ther 2021;27:e498.

• PubMed
Granger MM, Naranjo A, Bagatell R, Myeloablative busulfan/melphalan consolidation following induction chemotherapy for patients with newly diagnosed high-risk neuroblastoma: Children’s Oncology Group trial ANBL12P1. Transplant Cell Ther 2021;27:e498.)| false
• Search Google Scholar
• Export Citation

Clinicaltrials.gov Accessed November 29, 2023. Available at: https://www.clinicaltrials.gov/

• PubMed
Clinicaltrials.gov Accessed November 29, 2023. Available at: https://www.clinicaltrials.gov/)| false
• Export Citation

Holmes K, Potschger U, Pearson ADJ, et al. Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: a report from the HR-NBL1/SIOPEN study. J Clin Oncol 2020;38:2902–2915.

• PubMed
Holmes K, Potschger U, Pearson ADJ, Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: a report from the HR-NBL1/SIOPEN study. J Clin Oncol 2020;38:2902–2915.)| false
• Search Google Scholar
• Export Citation

von Allmen D, Davidoff AM, London WB, et al. Impact of extent of resection on local control and survival in patients from the COG A3973 study with high-risk neuroblastoma. J Clin Oncol 2017;35:208–216.

• PubMed
von Allmen D, Davidoff AM, London WB, Impact of extent of resection on local control and survival in patients from the COG A3973 study with high-risk neuroblastoma. J Clin Oncol 2017;35:208–216.)| false
• Search Google Scholar
• Export Citation

Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999;341:1165–1173.

• PubMed
Matthay KK, Villablanca JG, Seeger RC, Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s Cancer Group. N Engl J Med 1999;341:1165–1173.)| false
• Search Google Scholar
• Export Citation

Desai AV, Applebaum MA, Karrison TG, et al. Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer 2022;128:2967–2977.

• PubMed
Desai AV, Applebaum MA, Karrison TG, Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer 2022;128:2967–2977.)| false
• Search Google Scholar
• Export Citation

Mody R, Yu AL, Naranjo A, et al. Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group. J Clin Oncol 2020;38:2160–2169.

• PubMed
Mody R, Yu AL, Naranjo A, Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children’s Oncology Group. J Clin Oncol 2020;38:2160–2169.)| false
• Search Google Scholar
• Export Citation

Yalcin B, Kremer LC, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev 2015;2015:CD006301.

• PubMed
Yalcin B, Kremer LC, van Dalen EC. High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma. Cochrane Database Syst Rev 2015;2015:CD006301.)| false
• Search Google Scholar
• Export Citation

Kushner BH, Ostrovnaya I, Cheung IY, et al. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget 2016;7:4155–4166.

• PubMed
Kushner BH, Ostrovnaya I, Cheung IY, Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget 2016;7:4155–4166.)| false
• Search Google Scholar
• Export Citation

Ladenstein R, Potschger U, Pearson ADJ, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol 2017;18:500–514.

• PubMed
Ladenstein R, Potschger U, Pearson ADJ, Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol 2017;18:500–514.)| false
• Search Google Scholar
• Export Citation

Liu KX, Naranjo A, Zhang FF, et al. Prospective evaluation of radiation dose escalation in patients with high-risk neuroblastoma and gross residual disease after surgery: a report from the Children’s Oncology Group ANBL0532 study. J Clin Oncol 2020;38:2741–2752.

• PubMed
Liu KX, Naranjo A, Zhang FF, Prospective evaluation of radiation dose escalation in patients with high-risk neuroblastoma and gross residual disease after surgery: a report from the Children’s Oncology Group ANBL0532 study. J Clin Oncol 2020;38:2741–2752.)| false
• Search Google Scholar
• Export Citation

Braunstein SE, London WB, Kreissman SG, et al. Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: a report from the COG A3973 study. Pediatr Blood Cancer 2019;66:e27736.

• PubMed
Braunstein SE, London WB, Kreissman SG, Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: a report from the COG A3973 study. Pediatr Blood Cancer 2019;66:e27736.)| false
• Search Google Scholar
• Export Citation

Casey DL, Pitter KL, Kushner BH, et al. Radiation therapy to sites of metastatic disease as part of consolidation in high-risk neuroblastoma: can long-term control be achieved? Int J Radiat Oncol Biol Phys 2018;100:1204–1209.

• PubMed
Casey DL, Pitter KL, Kushner BH, Radiation therapy to sites of metastatic disease as part of consolidation in high-risk neuroblastoma: can long-term control be achieved? Int J Radiat Oncol Biol Phys 2018;100:1204–1209.)| false
• Search Google Scholar
• Export Citation

Polishchuk AL, Li R, Hill-Kayser C, et al. Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 2014;89:839–845.

• PubMed
Polishchuk AL, Li R, Hill-Kayser C, Likelihood of bone recurrence in prior sites of metastasis in patients with high-risk neuroblastoma. Int J Radiat Oncol Biol Phys 2014;89:839–845.)| false
• Search Google Scholar
• Export Citation

Yu AL, Gilman AL, Ozkaynak MF, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324–1334.

• PubMed
Yu AL, Gilman AL, Ozkaynak MF, Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 2010;363:1324–1334.)| false
• Search Google Scholar
• Export Citation

Yu AL, Gilman AL, Ozkaynak MF, et al. Long-term follow-up of a phase III study of ch14.18 (dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032. Clin Cancer Res 2021;27:2179–2189.

• PubMed
Yu AL, Gilman AL, Ozkaynak MF, Long-term follow-up of a phase III study of ch14.18 (dinutuximab) + cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032. Clin Cancer Res 2021;27:2179–2189.)| false
• Search Google Scholar
• Export Citation

Ladenstein R, Potschger U, Valteau-Couanet D, et al. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol 2018;19:1617–1629.

• PubMed
Ladenstein R, Potschger U, Valteau-Couanet D, Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. Lancet Oncol 2018;19:1617–1629.)| false
• Search Google Scholar
• Export Citation

Ladenstein R, Potschger U, Valteau-Couanet D, et al. Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1). Cancers (Basel) 2020;12:309.

• PubMed
Ladenstein R, Potschger U, Valteau-Couanet D, Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN high-risk neuroblastoma 1 trial (HR-NBL1). Cancers (Basel) 2020;12:309.)| false
• Search Google Scholar
• Export Citation

Sholler GLS, Ferguson W, Bergendahl G, et al. Maintenance DFMO increases survival in high risk neuroblastoma. Sci Rep 2018;8:14445.

• PubMed
Sholler GLS, Ferguson W, Bergendahl G, Maintenance DFMO increases survival in high risk neuroblastoma. Sci Rep 2018;8:14445.)| false
• Search Google Scholar
• Export Citation

Oesterheld J, Ferguson W, Kraveka JM, et al. Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons. J Clin Oncol 2024;42:90–102.

• PubMed
Oesterheld J, Ferguson W, Kraveka JM, Eflornithine as postimmunotherapy maintenance in high-risk neuroblastoma: externally controlled, propensity score-matched survival outcome comparisons. J Clin Oncol 2024;42:90–102.)| false
• Search Google Scholar
• Export Citation

Prescribing information: eflornithine tablets, for oral use. Accessed April 30, 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215500s000lbl.pdf

• PubMed
Prescribing information: eflornithine tablets, for oral use. Accessed April 30, 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215500s000lbl.pdf)| false
• Search Google Scholar
• Export Citation

Yanik GA, Parisi MT, Shulkin BL, et al. Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. J Nucl Med 2013;54:541–548.

• PubMed
Yanik GA, Parisi MT, Shulkin BL, Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children’s Oncology Group. J Nucl Med 2013;54:541–548.)| false
• Search Google Scholar
• Export Citation

Weiss BD, Yanik G, Naranjo A, et al. A safety and feasibility trial of (131) I-MIBG in newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group study. Pediatr Blood Cancer 2021;68:e29117.

• PubMed
Weiss BD, Yanik G, Naranjo A, A safety and feasibility trial of (131) I-MIBG in newly diagnosed high-risk neuroblastoma: a Children’s Oncology Group study. Pediatr Blood Cancer 2021;68:e29117.)| false
• Search Google Scholar
• Export Citation

Diller L, London W, Bardwell J, et al. Surviving high risk neuroblastoma: a preliminary descriptive report from Project LEAHRN (Late Effects After High-Risk Neuroblastoma) [abstract]. Presented at the Advances in Neuroblastoma Research (ANR) Conference, January 25–27, 2021.

• PubMed
Diller L, London W, Bardwell J, Surviving high risk neuroblastoma: a preliminary descriptive report from Project LEAHRN (Late Effects After High-Risk Neuroblastoma) [abstract]. Presented at the Advances in Neuroblastoma Research (ANR) Conference, January 25–27, 2021.)| false
• Search Google Scholar
• Export Citation

Friedman DN, Henderson TO. Late effects and survivorship issues in patients with neuroblastoma. Children (Basel) 2018;5:107.

• PubMed
Friedman DN, Henderson TO. Late effects and survivorship issues in patients with neuroblastoma. Children (Basel) 2018;5:107.)| false
• Search Google Scholar
• Export Citation

Laverdiere C, Liu Q, Yasui Y, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009;101:1131–1140.

• PubMed
Laverdiere C, Liu Q, Yasui Y, Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009;101:1131–1140.)| false
• Search Google Scholar
• Export Citation

Hesko C, Liu W, Srivastava DK, et al. Neurocognitive outcomes in adult survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. Cancer 2023;129:2904–2914.

• PubMed
Hesko C, Liu W, Srivastava DK, Neurocognitive outcomes in adult survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. Cancer 2023;129:2904–2914.)| false
• Search Google Scholar
• Export Citation

Landier W, Knight K, Wong FL, et al. Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales–a report from the Children’s Oncology Group. J Clin Oncol 2014;32:527–534.

• PubMed
Landier W, Knight K, Wong FL, Ototoxicity in children with high-risk neuroblastoma: prevalence, risk factors, and concordance of grading scales–a report from the Children’s Oncology Group. J Clin Oncol 2014;32:527–534.)| false
• Search Google Scholar
• Export Citation

Friedman DN, Goodman PJ, Leisenring WM, et al. Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the childhood cancer survivor study. J Natl Cancer Inst 2024;116:885–894.

• PubMed
Friedman DN, Goodman PJ, Leisenring WM, Impact of risk-based therapy on late morbidity and mortality in neuroblastoma survivors: a report from the childhood cancer survivor study. J Natl Cancer Inst 2024;116:885–894.)| false
• Search Google Scholar
• Export Citation